This is a clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential of GMI-1070 in African-American Adult subjects. This is conducted as part of standard drug development.
Safety
Study Type
INTERVENTIONAL
Purpose
OTHER
Masking
TRIPLE
Enrollment
48
Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
Pfizer Investigational Site
San Antonio, Texas, United States
QTc, during rivipansel treatment period
QTc, using Fridericia's correction method (QTcF) at each time point during rivipansel treatment period.
Time frame: prior to dose, through 72 hours after dosing
QTc, during placebo treatment period
QTc, using Fridericia's correction method (QTcF) at each time point during placebo treatment period.
Time frame: prior to dose, through 72 hours after dosing
QTc, during moxifloxacin treatment period
QTcF, or any other appropriate correction method at each postdose time point of moxifloxacin treatment.
Time frame: prior to dose, through 72 hours after dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.